Fuerjia's Market Value Plummets 60% as Soaring Marketing Costs Devour Profits

Fuerjia: No Current Plans to Establish Medical Device R&D Subsidiary in Hainan

Harbin Fuerjia Technology Co., Ltd. (301371.SZ) Reports Q3 Results, Net Profit Drops 36.73% to 325 Million Yuan

Harbin Fuerjia Technology Co., Ltd. Clarifies No Current Involvement in Pore-Reduction and Whitening Massagers

Harbin Fuerjia Technology's CFO Deng Baijiao Resigns, Li Zhengde Takes Over

Skincare and Daily Chemical Half-Year Reports: Bloomage Biotechnology Corporation Limited, Yunnan Botanee Bio-Technology Group Co.,Ltd., Harbin Fuerjia Technology Co.,Ltd., and Lushang Freda Pharmaceutical Co.,Ltd. Struggle to Reverse Performance Decline with Double Drops in H1 2025

Jinbo Biology Reports Revenue and Profit Growth in H1 2025, But Growth Rate Slows Significantly Amid Core Business Deceleration and Surging Sales Expenses

Medical Aesthetics Companies' Mid-Year Performance: Giant Bio Leads While Huaxi Bio and Fuerjia Seek Transformation as Industry Acceleration Continues

Medical Beauty Semi-Annual Report | Harbin Fuerjia Technology Co.,Ltd. Reports Dual Decline in H1 2025 Performance with Rising Inventory Pressure, Potentially Experiencing Growing Pains from Channel Transformation and Value Reassessment

Harbin Fuerjia Technology Announces Half-Year Report with 32.54% Decline in Net Profit

Harbin Fuerjia Technology Co.,Ltd. (301371.SZ) Reports Half-Year Results with Net Profit of 230 Million Yuan, Down 32.54%